One of Italy’s largest pharmaceutical companies that is publicly traded (meaning its shares are sold on the stock market) may soon be bought by a private investment firm. A private equity company is currently in discussions to take over the company, which would change its ownership from public to private. This means the company would no longer be listed on the stock exchange, and its shares would no longer be available for public purchase. The move is part of a broader trend where private investors take over publicly traded companies to manage them differently, often with the goal of improving efficiency or long-term growth. The pharmaceutical industry uses such transactions to strengthen companies’ positions in the market.